Bathing effects of east saline groundwater concentrates on allergic (atopic) dermatitis-like skin lesions induced by 2,4-dinitrochlorobenzene in hairless mice

CHOONG-GON KIM1*, JI-EUN LEE2,3*, DA-GEUM JEONG1, YOUN-HO LEE1, SANG-IN PARK2,3, DAE-GEON LEE2,3, CHANG-HYUN HAN4, SU-JIN KANG2,5, CHANG-HYUN SONG2,3, SEONG-HUN CHOI1, YOUNG-JOON LEE2,5 and SAE-KWANG KU2,3

1Biological Oceanography and Marine Biology Division, KIOST, Ansan, Gyeonggi 15627; 2The Medical Research Center for Globalization of Herbal Medicine; 3Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University, Gyeongsan, Gyeongsangbuk-do 38610; 4Department of Medical History and Literature Group, Korea Institute of Oriental Medicine, Daejeon 34054; 5Department of Preventive Medicine, College of Korean Medicine, Daegu Haany University, Gyeongsan, Gyeongsangbuk-do 38610, Republic of Korea

Received June 28, 2016; Accepted March 6, 2017

Abstract. In the present study, it was evaluated whether east saline groundwater concentration solution (ESGWc) exerted a favorable inhibitory effect on 2,4-dinitrochlorobenzene (DNCB)-induced allergic/atopic-like dermatitis (AD). AD was induced and boosted by sensitization with DNCB via topical application on the dorsal back skins. Mice with DNCB-induced AD were bathed in 100-, 200- and 400-fold diluted ESGWc. After 6 weeks bathing, changes to body weight, clinical skin severity scores, scratching behavior, serum total immunoglobulin (Ig)E levels, submandibular lymph node and spleen weights, splenic cytokine levels, skin cytokine mRNA expressions, antioxidant defense systems and superoxide anion productions were recorded to determine the effects of bathing on the histopathology of dorsal back skin tissues. All DNCB-induced mice demonstrated that the induction of AD through IgE-mediated hypersensitivities, oxidative stresses, activation of MMP and apoptosis of keratinocytes resulted in no significant differences in body weight between the different groups at each time point following initial sensitization. However, markers of DNCB-induced AD were significantly inhibited (P<0.05) in a concentration-dependent manner following bathing in all concentrations of ESGWc. The results obtained in the present study suggest that bathing in ESGWc may have favorable protective effects against DNCB-induced AD due to favorable systemic and local immunomodulatory effects, active cytoprotective anti-apoptotic effects, inhibitory effects of matrix metalloproteinase activity, and anti-inflammatory and antioxidative effects.

Introduction

Allergic/atopic dermatitis (AD) is characterized by various symptoms, including itching, erythema, eczema skin lesions, chronic relapse and pruritus (1). Patients with AD, may experience itchy skin, inducing scratching behavior and increasing the induction of pro-inflammatory cytokines (1,2). This, in turn, triggers immune cells and activates an inflammatory cycle of allergic dermatitis that is accompanied by erythema, keratosis and scaling of the skin (2). Due to an imbalanced immune response to various allergens (3), there are a number of symptoms, such as erythema, keratosis and scaling, that occur during AD. Another characteristic of the allergic immune system is the ability to produce a greater number of immunoglobulin E (IgE) antibodies and type 2 helper T cells (Th2), which are pivotal for IgE synthesis (4,5). Th2 cells predominantly induce the production of interleukin (IL) families and these cytokines are associated with the specific function of immune cells in AD (5). IgE is used as an indicator of AD severity and abnormalities of the skin barrier, a key feature of AD (6). During allergic inflammation, IgE and IgE-mediated mast cell and eosinophil activation contribute to AD (4,5). In addition, IgE is able to sensitize mast cells in the skin when cell-bound IgE is cross-linked by allergens, culminating in the production of inflammatory mediators, such as interleukins (IL)-4, -5 and -13 and tumor necrosis factor (TNF)-α (5). The cytokines IL-4 and IL-13 released by mast cells contribute to...
the Th2 response (5), TNF-α produced by macrophages also serves an important role in the acute phase of AD (7) and it has been demonstrated that oxidative stress is involved in the pathogenesis of AD (3,8).

To relieve the symptoms of AD, adrenocorticosteroids and anti-histamine agents have been utilized due to their ameliorating effects. However, they evoke severe side effects (9), therefore alternative therapies and natural products have been investigated for the treatment of AD (3,6). Hydrotherapy is regarded as a complementary therapy for AD in the therapeutic field (10). A number of studies have investigated the association between different water baths and their beneficial effects on dermatological disorders (11,12). Different types of water have demonstrated unique and distinct characteristics, although each water type differs in composition (13). Hydrotherapy may regulate lymphocyte proliferation and cytokine production (13) due to the antioxidant effects of the mineral composition of different types of water (14,15). Various seawaters exhibit protective effects against various types of dermatitis (16,17). Notably, the present study is a follow-up to a previous study by the present authors, in which it was demonstrated that bathing in four different types of seawater collected around Korea induces favorable systemic and local immunomodulatory effects, active cytoprotective anti-apoptotic effects, inhibitory effects of matrix metalloproteinase (MMP) activity, anti-inflammatory and antioxidative effects against 2,4-dinitrochlorobenzene (DNCB)-induced AD (18). The four types of water included: West surface seawater (WSSW) collected around Wepo-ri, Ganghwa-do, Korea; west saline groundwater (WSGW) collected at Yonggungoncheon, Seokmo-do, Korea; east surface seawater (ESSW) collected around Nagok-ri, Uljin, Korea; and east saline groundwater (ESGW) collected around Hoojeong-ri, Uljin, Korea (18). The greatest protective effects were demonstrated by ESGW, followed by WSGW, ESSW and WSSW, respectively (18).

As ESGW demonstrated the most protective effect among the four different types of seawater collected around Korea (18), the objective of the present study was to evaluate the potential concentration-dependent inhibitory effect of three different dilutions (100-, 200- and 400-fold dilutions) of ESGW concentration solution (50X; ESGWc) on DNCB-induced AD-like skin lesions in hairless mice following 6 weeks of bathing (once daily for 42 days for 20 min/day). Bathing is regarded as a method of developing a novel alternative therapy for AD patients (10); in the present study, it was used to determine the inhibitory effect of ESGWc against DNCB-induced AD-like skin lesions. Results were compared with those of 1% dexamethasone (DEXA) topically applied to the mice (once a day for 42 days) as a control treatment (18). Among animal models, DNCB-stimulated mice exhibit diverse symptoms similar to those of AD, including skin infiltration of inflammatory cells and increases in mast cell numbers and serum IgE levels (19). Therefore, a hairless murine model of DNCB-induced AD was selected to identify the bathing effects of various types of seawaters.

Materials and methods

**Animal model.** A total of 110 6-week SKH-1 female hairless mice were obtained from Orient Bio, Ltd. (Seungnam, Korea; body weight ranged in 20~23 g upon receipt) and 6 groups (each, n=8) were selected 5 weeks following DNCB sensitization based on body weight (intact control: 27.51±1.07 g; DNCB treated mice: 27.37±0.87 g), clinical skin severity scores (intact control: 1.00±0.76 scores; DNCB treated mice: 12.45±1.01 scores) and scratching behavior (intact control: 11.88±5.46 frequencies/30 min; DNCB treated mice: 478.93±94.64 frequencies/30 min). Animals were acclimatized for 10 days and placed in polycarbonate cages (4 mice/cage) in a temperature (20-25°C) and humidity (50-55%) controlled room. Mice were housed under a 12 h light/dark cycle and standard rodent chow (Samyang Corp., Seoul, Korea) and water were available *ad libitum*. All laboratory animals were treated according to the national regulations of the usage and welfare of laboratory animals, and approved by the Institutional Animal Care and Use Committee of Daegu Haany University (Gyeongsan, Korea; approval no. DHU2015-068). The mice were sub-divided into six groups, comprising three control groups (intact, DNCB treatment for negative control and DEXA treatment for reference control) and three treatment groups (ESGWc 100-, 200- and 400-fold treatment).

**Preparation of seawaters and DEXA.** Colorless clear solutions of ESGWc were prepared by AriBio Inc. (Seoul, Korea). Briefly, ESGW was collected around Hoojeong-ri (Gyeongsang, Korea) and a 50-fold concentrated solution was created using a rotary evaporator (N-1200B; Tokyo Rikakikai Co., Ltd., Tokyo, Japan). In addition, appropriate amounts of Ca-lactate and NaCl were separately prepared to supplement for the reduction in minerals during the concentration process. Salinity and mineral compositions of ESGWc compared with ESGW and general underground water are listed in Table I. White powders of water-soluble DEXA (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) were obtained and used in the present study as a potent reference agent. All test materials used in the present experiment were stored at 4°C in a refrigerator to protect from light and humidity until usage.

**Induction of AD.** AD-like dermatitis was induced in mice by sensitization with 10 mg/ml DNCB (Sigma-Aldrich; Merck KGaA; dissolved in a 3:1 mixture of acetone and olive oil) once a day for 1 week and boosted by 5 mg/ml DNCB three times a week for 28 days, according to established previous methods (3,18). DNCB solutions were topically applied on the dorsal back skins of mice in a volume of 200 µl/mouse. In control mice, vehicle (3:1 mixtures of acetone and olive oil) was topically applied, instead of DNCB solution.

**Bathing and topical application of DEXA.** ESGWc 100-fold dilutions (2-fold dilutions of original ESGW) were selected as the highest concentrations based on a previous study investigating the effects of ESGW on DNCB hairless mice, in which favorable anti-AD effects were demonstrated at this concentration (18). In addition, 200- and 400-fold dilutions were selected as the middle and lowest concentrations, respectively, using common ratio 2. ESGWc were 100-, 200- and 400-fold diluted with distilled water, using 10, 5 and 2.5 ml ESGWc in 990, 995 and 997.5 ml of distilled water, respectively. Appropriate amounts of Ca-lactate and NaCl were added to supplement for the reduction in minerals during the concentration process with a Ca:Mg balance, salinity and conductance adjustment of
2.11 and 7.40, 1.06 and 3.70, 0.53 and 1.85 g in 100-, 200- and 400-fold dilutions of ESGWc, respectively. All mice in the ESGWc groups were allowed to swim freely in the ESGWc in mouse polycarbonate cages (200x260x130 mm; DJ-101; Daejong Instrument Industry Co., Seoul, Korea), which contained ~1,900 ml of warm water at ~37°C and bottom plates 4 cm deep, for 20 min/day.

DEXA treatment was performed as follows: Water-soluble DEXA was dissolved in distilled water to form a 1% solution and topically applied to the dorsal back skins (200 µl/mouse) once daily for 6 weeks, 5 weeks after initial DNCB sensitization. Intact and DNCB control mice bathed in distilled water instead of test waters in the present experiment to induce the same swimming stresses. Test waters and 1% DEXA solutions were warmed to ~37°C at least 30 min prior to bathing to avoid cooling irritations. A total bathing period of 6 weeks was selected for the present study, based on previous findings of the bathing effects of mineral-rich water (20) and the results of a previous study into the bathing effects of various seawaters collected around Korea (18).

Changes in body weight. Changes in body weight were measured once a week, from 1 day prior to initial DNCB sensitization to the end of the 6-week bathing period in the three different concentrations of ESGWc, distilled water or topical application of 1% DEXA, using an automatic electronic balance (Precisa Gravimetrics AG, Dietikon, Switzerland). To reduce individual differences, the total body weight gains during the 11-week whole experimental period and the total body weight gains during the 6-week bathing or topical application of 1% DEXA period were calculated.

Evaluation of clinical skin severity scores. Five signs of skin lesions, including pruritus/itching, erythema/hemorrhage, edema, excoriations/erosion and scaling/dryness were graded as follows: 0, (no symptoms); 1, (mild); 2, (moderate); and 3, (severe). Total scores (maximum=15) were regarded as the clinical skin severity score, in accordance with previous reports (3,18), with some modifications. Scoring was conducted once a week for 6 weeks, starting 5 weeks after DNCB sensitization and ending 24 h after the final bathing (11 weeks after first DNCB sensitization). An additional scoring was conducted 3 days after initial bathing (38 days after initial DNCB sensitization).

Evaluation of scratching behavior. Each mouse from each group was placed individually in a routine polycarbonate mouse cage and their behavior was monitored for 30 min once a week, from 5 weeks after initial DNCB sensitization to 24 h after final bathing (11 weeks after first DNCB sensitization) including 3 days after initial bathing (38 days after first DNCB sensitization), respectively. Scratching of the rostral back and biting of the caudal back were observed; scratching movements by the hind paw were defined as a scratching bout that ended when the mouse either licked its hind paw or placed its hind paw back on the floor. A series of one or more biting movements was counted as one episode that ended when the mouse returned to the straight-forward position (3).

 Serum total IgE level measurement. At 6 weeks after the initial bathing, ~1 ml venous blood was collected from the vena cava under anesthesia with 2 to 3% isoflurane (Hana Pharm Co., Ltd., Hwasung, Korea) and maintained with 1 to 1.5% isoflurane in a mixture of 70% N2O and 28.5% O2, and serum was separated by centrifugation at 21,000 x g for 10 min at 4°C using a clotting-activated serum tube (BD Biosciences, San Jose, CA, USA). Total IgE levels in sera were determined by sandwich ELISA using the mouse IgE ELISA kit (cat. no. 555248, BD Biosciences), according to previous methods (3,16,18). Briefly, plates were coated with capture antibody in ELISA coating buffer and incubated overnight at 4°C. Subsequently, plates were washed with phosphate-buffered saline (PBS)-TWEEN-20 (0.05%) and blocked with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) in PBS for 1 h at 20°C. Serial dilutions of standard antigen or sample in dilution buffer (10% FBS in PBS) were added to the plates and plates were incubated for 2 h at 20°C. Following three washes with PBS-Tween-20 (0.05%), biotin-conjugated anti-mouse IgE and streptavidin-horseradish peroxidase conjugate were added to the plates, according to the ELISA kit protocols, and plates were incubated for 1 h at 20°C. Finally, tetramethylbenzidine substrate solution was added to the plates and following 15-min incubation in the dark, a 2 N H2SO4 solution was added to stop the reaction. Optical densities were measured at 450 nm using an automated ELISA plate reader (Tecan Group, Ltd., Männedorf, Switzerland).

Lymphatic organ weight measurements. At 24 h after the end of the forty second bath, the mice were sacrificed by exsanguination through vena cava under anesthesia with 3% isoflurane and dissected. The spleen and left submandibular lymph node (LN) in each mouse were collected following.

| Seawater | Salinity,% | Conductance, ms/cm | Balance, Ca:Mg | Mineral compositions, mg/l |
|----------|------------|-------------------|----------------|-------------------|
| GUGW     | 2.11       | 7.40              | 1.06:1         | Ca 81.00, Mg 121.00, K 12.00, Na 569.00 |
| ESGW     | 24.20      | 38.02             | 1.80:1         | Ca 1,720.00, Mg 950.00, K 100.00, Na 6,000.00 |
| ESGWc    | 0.53       | 1.85              | 1.19:1         | Ca 53,707.00, Mg 45,080.00, K 2,800.00, Na 15,000.00 |

GUGW, general underground water; ESGW, east saline groundwater; ESGWc, east saline groundwater concentration solution (50X).
elimination of the surrounding connective tissues, muscles and debris. Individual weights of lymphatic organs were measured in grams to record absolute wet-weight. To reduce the individual body weight differences, the relative weight (% of body weight) of lymphatic organs was calculated using body weight at sacrifice and absolute organ weight according to previously established methods (18).

**Splenic cytokine content measurements.** Splenic concentrations of TNF-α, IL-1β and IL-10 were measured by ELISA using commercially available kits, including a mouse TNF-α ELISA kit (cat. no. 558534, BD Biosciences), a mouse IL-1β ELISA kit (cat. no. MBS824757) and a mouse IL-10 ELISA kit (cat. no. MBS8244590; both MyBioSource, Inc., San Diego, CA, USA), respectively, as previously described (18). Tissue samples (10-15 mg) were homogenized in a tissue grinder containing 1 ml lysis buffer (PBS containing 2 mM phenylmethylsulfonyl fluoride and 1 mg/ml aprotinin, leupeptin, and pepstatin A, all obtained from Sigma-Aldrich; Merck KGaA), as described by Clark et al (21). Analysis was performed with 100 ml standard (diluted in lysis buffer) or 10, 50 or 100 ml tissue homogenate. Each sample was run in duplicate and a portion of the sample was analyzed for protein. Data were expressed as pg/mg of protein. For each assay, a standard curve was generated and based on replicates of the measured absorbance, demonstrated an average coefficient of variance of <10%.

**Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** Total RNA was extracted from skin tissue samples using TRIzol™ reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to a previously described method (18). cDNA was synthesized from 2 µg total RNA in a final reaction volume of 20 µl. RNA was reverse transcribed using a High-Capacity cDNA Reverse Transcription kit (cat. no. 43-749-67; Applied Biosystems; Thermo Fisher Scientific, Inc.), according to the manufacturer’s instructions. Briefly, a mixture of 2 µl RT buffer, 0.8 µl dNTP mix, 2 µl RT primers, 1 µl MultiScribe™ reverse transcriptase, 1 µl RNase inhibitor and 3.2 µl nuclease-free distilled water was prepared and mixed with 10 µl RNA sample. Reverse transcription was performed as follows: 25˚C for 10 min, 37˚C for 120 min, 85˚C for 5 min. RT-qPCR analysis was carried out with a CFX96™ Real-Time System (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using iTaq™ SYBR-Green (Bio-Rad Laboratories). The mixture was kept in a water bath at 100˚C for 15 min. Levels of malondialdehyde (MDA), an intermediate product of lipoperoxidation, were determined by difference between absorbances at 535 and 572 nm on a microplate spectrophotometer reader (Tecan Group, Ltd., Männedorf, Switzerland) and the results were reported as nM/mg of protein (18).

**Superoxide anion production.** The quantification of superoxide anion production in skin tissue homogenates (10 mg/ml in 1.15% KCl; tissue was obtained after sacrifice) was performed using the nitroblue tetrazolium (NBT) assay, as previously described (25). For this assay, 10% trichloroacetic acid (Sigma-Aldrich; Merck KGaA) was added to the homogenate to precipitate proteins. This mixture was then centrifuged for 3 min at 1,000 x g at 4˚C. The protein-free sample was extracted and 0.67% thio-barbituric acid (Sigma-Aldrich; Merck KGaA) was added. The mixture was kept in a water bath at 100˚C for 15 min. Levels of malondialdehyde (MDA), an intermediate product of lipoperoxidation, were determined by difference between absorbances at 535 and 572 nm on a microplate spectrophotometer reader (Tecan Group, Ltd., Männedorf, Switzerland) and the results were reported as nM/mg of protein (18).

**Histopathology.** Samples from dorsal back skins, spleen and left submandibular LN were separated and fixed in 10% neutral buffered formalin at room temperature for 24 h, embedded in paraffin, sectioned into 3-4-µm sections and stained with hematoxylin and eosin (H&E) for general histopathology, Masson’s trichrome (MT) for collagen fiber or toluidine blue for mast cells, according to previously described methods (18). Following this, the histopathological profiles of each sample were observed under a light microscope (Eclipse 80i; Nikon Corporation, Tokyo, Japan). Mean epithelial thicknesses of the epidermis (µm), mean numbers of inflammatory and mast cells infiltrated in the dermis (cells/mm² of dermis), total splenic thicknesses (mm/central regions), mean numbers of white pulp
Table II. Oligonucleotides for reverse transcription-quantitative polymerase chain reaction.

| Target                          | Direction | Sequence (5'-3')                             | Gene bank number |
|--------------------------------|-----------|----------------------------------------------|------------------|
| Tumor necrosis factor-α         | Forward   | CCTGTAGCCCCACGTCGTAGC                        | NM_013693.2      |
|                                | Reverse   | 5TTGACCTCAGCGCTGAGTTG                        |                  |
| Interleukin-4                   | Forward   | GAATGTACCGAGGCCATATC                         | NM_021283.2      |
|                                | Reverse   | CTCAGTACTACGGATAATCCA                       |                  |
| Interleukin-5                   | Forward   | TCACCGAGCTCTGTTGACAA                        | NM_010558.1      |
|                                | Reverse   | CCACACTTCCTCTTGGCC                         |                  |
| Interleukin-13                  | Forward   | GACCGAGAGATTTGATG                           | NM_008355.3      |
|                                | Reverse   | CACGCAAGTCTGATG                             |                  |
| Glyceraldehyde                  | Forward   | CATCTTCCAGGCGAGACC                         | NM_008084.2      |
| 3-phosphate dehydrogenase       | Reverse   | AAGCCATGCACATGGTCT                          |                  |

(white pulps/mm² of splenic parenchyma) and red pulp cells (x10^3 cells/mm² of splenic parenchyma), total submandibular LN thicknesses (mm/central regions), cortex lymphoid follicle numbers (follicles/mm² of cortex) and mean thicknesses (µm/LN) of submandibular LN were calculated for general histomorphometrical analysis using a computer-assisted image analysis program (iSolution FL v. 9.1; IMT i-solution Inc., Irvine, CA, USA) under H&E stain and collagen fiber occupied regions in the dermis (%/mm² of dermis) under an MT stain, according to previously established methods (18,27). The histopathologist was blinded to the groups when this analysis was performed.

Immunohistochemistry. Following deparaffinization of prepared skin using xylene, submandibular LN or spleen histological paraffin sections, citrate buffer antigen (epitope) retrieval pretreatment was conducted, as previously described (18). Briefly, a water bath with a staining dish containing 10 mM citrate buffer (pH 6.0) was pre-heated until the temperature reached 95-100°C. Slides were immersed in the staining dish and the lid was placed loosely on the staining dish. Slides were incubated in the water bath for 20 min and then the water bath was turned off. Subsequently, the staining dish was placed at room temperature for 20°C to allow the slides to cool. Following epitope retrieval, sections were immunostained using avidin-biotin complex (ABC) methods for caspase-3, poly ADP ribose polymerase (PARP), nitrotyrosine (NT), 4-hydroxynonenal (4-HNE), MMP-9, interferon (IFN)-γ, inducible nitric oxide synthase (iNOS), IL-1β, IL-2 and TNF-α, following protocols recorded in previous studies (18,27). Briefly, endogenous peroxidase activity was blocked by incubation in methanol and 0.3% H₂O₂ at room temperature for 30 min, and non-specific binding of immunoglobulin was blocked with 1% normal horse serum blocking solution (1:100; Vector Laboratories, Inc., Burlingame, CA, USA) at room temperature for 1 h in a humidity chamber. Primary antisierum (listed in Table III) was treated overnight at 4°C in a humidity chamber and then incubated with biotinylated universal secondary antibody (Vectastain Elite ABC kit; 1:50; Vector Laboratories, Inc.) and ABC reagents (Vectastain Elite ABC kit; 1:50; Vector Laboratories, Inc.) for 1 h at room temperature in a humidity chamber. Finally, a DAB peroxidase substrate kit (cat. no. SK-4100; Vector Laboratories, Inc.) was applied for 3 min at room temperature. All sections were rinsed in 0.01 M PBS three times between steps. The cells or fibers occupied by >30% of immunoreactivities, the density of each antisierum (for caspase-3, PARP, NT, 4-HNE, MMP-9, IFN-γ, iNOS, IL-1β, IL-2 and TNF-α) as compared with intact dermal keratinocytes or dermal fibers, were regarded as positive, and the mean numbers of caspase-3, PARP, NT and 4-HNE immunoreactive cells in the epidermis (cells/100 epithelial cells), and mean IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cell numbers in the dermis (cells/mm² of dermis), spleen (cells/mm² of spleen) and submandibular LN (cells/mm² of LN) were also counted using an automated image analysis process (iSolution FL v. 9.1; IMT i-Solution Inc., Irvine, CA, USA), as previously described (18,27) with some modifications. In addition, the occupied percentages by MMP-9 immunoreactive fibers were also calculated in the dermis (%/mm² of dermis) as MMP-9 immunoreactivities in the present experiment. The histopathologist was blinded to the group distribution when performing the analysis.

Statistical analyses. All data were expressed as the mean ± standard deviation of eight hairless mice. Multiple comparison tests for different dose groups were conducted. Variance homogeneity was examined using Levene's tests. If the Levene's test indicated no significant deviations from variance homogeneity, the obtained data were analyzed by one way analysis of variance, followed by least-significant differences multi-comparison test to determine which pairs of group comparison were significantly different. In the case of significant deviations from variance homogeneity being observed in the Levene's test, a non-parametric comparison test, Kruskal-Wallis H test, was conducted. When a significant difference was observed with the Kruskal-Wallis H test, the Mann-Whitney U test was conducted to determine the specific pairs of group comparisons that were significantly different. Statistical analyses were conducted using SPSS v. 14.0 for Windows (SPSS, Inc., Chicago, IL, USA). In addition, the percentage changes between intact vehicle and DNCB control were calculated to observe the severities of AD-like lesions induced by DNCB in the present study, and the percentage changes as compared with DNCB control and hairless mice bathing in seawaters or receiving
KIM et al: ANTI-ALLERGIC EFFECTS OF GROUNDWATER CONCENTRATES

Results

Changes in body weight. No significant differences in body weight gains were observed among any of the groups during the total 11-week experimental period. During the 6-week bathing period, DNCB control mice demonstrated similar body weights to the intact vehicle control mice, apart from significant decreases in body weight identified in the DNCB-sensitized (DEXA-treated and ESGWc 100-, 200-, or 400-fold) mice on days 6 and 7 days after initial DNCB sensitization compared with the intact vehicle control mice (P<0.05). Topical application of 1% DEXA and bathing with all three concentrations of ESGWc did not significantly alter body weight compared with mice in the DNCB control group throughout the entire experimental period of the present experiment (Fig. 1).

Clinical skin severity score changes. DNCB control mice exhibited significant increases in clinical skin severity scores from 24 h before initial bathing up until the end of the experimental period compared with intact vehicle control mice (P<0.05; Table IV). However, significant decreases in clinical skin severity scores were observed in mice receiving topical application of 1% DEXA, from 1 week after initial topical application up until the end of the experiment, as compared with DNCB control mice (P<0.05). Significant decreases in

dermalitis; DNCB, 2,4-dinitrochlorobenzene; DEXA, dexamethasone; ESGWc, east saline groundwater concentration solution (50X); Before, 1 day before initial DNCB sensitization.

Figure 1. Body weight changes during 6 weeks bathing in ESGWc or topical application of 1% DEXA in mice with DNCB-induced AD. On day 7, DNCB boosting was initiated and bathing in ESGWc or application of DEXA began on day 35. The arrow indicated that all animals were fasted overnight on day 77 prior to sacrifice. Values are expressed as the mean ± standard deviation (n=8). *P<0.05 vs. all treatment groups. AD, allergic/atopic-like dermatitis; DNCB, 2,4-dinitrochlorobenzene; DEXA, dexamethasone; ESGWc, east saline groundwater concentration solution (50X); Before, 1 day before initial DNCB sensitization.

All antiserums were diluted with 0.01 M phosphate buffered saline. IL, interleukin.

| Product | Catalog number | Supplier | Dilution |
|---------|----------------|----------|----------|
| Anti-cleaved caspase-3 (Asp175) polyclonal antibody | 9661 | Cell Signaling Technology Inc., Danvers, MA, USA | 1:400 |
| Anti-cleaved poly(ADP-ribose) polymerase (Asp214) specific antibody | 9545 | Cell Signaling Technology Inc. | 1:100 |
| Anti-4-Hydroxynonenal polyclonal antibody | Ab46545 | Abcam, Cambridge, UK | 1:100 |
| Anti-Nitrotyrosine polyclonal antibody | 06-284 | EMD Millipore, Billerica, MA, USA | 1:200 |
| Anti- Matrix metalloprotease-9 mouse antibody | Ab38898 | Abcam | 1:100 |
| Anti-interferon γ antibody | AF781 | R&D Systems, Inc., Minneapolis, MN, USA | 1:100 |
| Anti-IL-2 antibody | BAF1815 | R&D Systems, Inc. | 1:100 |
| Anti-tumor necrosis factor-α antibody | sc-52746 | Santa Cruz Biotechnology, Inc., Dallas, TX, USA | 1:200 |
| Anti-nitric oxide synthase2 (N-20) polyclonal antibody | sc-651 | Santa Cruz Biotechnology, Inc. | 1:100 |
| Anti-IL-1β (H-153) polyclonal antibody | sc-7884 | Santa Cruz Biotechnology, Inc. | 1:100 |
| Detection kits | | | |
| Vectastain Elite ABC Kit | PK-6200 | Vector Laboratories, Inc., Burlington, CA, USA | 1:50 |
| Peroxidase substrate kit | SK-4100 | Vector Laboratories, Inc. | 1:50 |
Changes in scratching behavior. DNCB control mice exhibited significant increases in scratching behavior from 24 h before initial bathing up until the end of the experimental period, as compared with intact vehicle control mice (P<0.05; Table V). However, these increases in scratching behavior were significantly inhibited by topical application of 1% DEXA from 1 week after initial topical application until the end of the experimental period, compared with DNCB control mice (P<0.05). In addition, significant decreases in scratching behaviors were detected from 2 weeks after initial bathing in all three concentrations of ESGW in a concentration-dependent manner, compared with DNCB control mice throughout the experimental period (P<0.05; Table V).

Effects on total serum IgE levels. Significant increases in total serum IgE levels were detected in DNCB control mice compared with intact vehicle control mice (P<0.05; Fig. 2). However, significant decreases of total serum IgE levels were detected by topical treatment of 1% DEXA and also in a concentration-dependent manner, compared with DNCB control mice (P<0.05; Fig. 2).

Changes in submandibular LN and spleen weights. Significant increases of submandibular LN and spleen absolute and relative weights were detected in DNCB control mice compared with intact vehicle control mice (P<0.05; Table VI). However,
Table VI. Changes in lymphatic organ weights after 6 weeks of bathing in ESGWc or topical application of DEXA in mice with DNBC-induced AD.

| Group                  | Absolute weight, g | Relative weight, % of body weight |
|------------------------|--------------------|-----------------------------------|
|                        | Spleen             | Submandibular LN                   |
| Controls               |                    |                                   |
| Intact                 | 0.093±0.012        | 0.008±0.002                       |
| DNBC                   | 0.242±0.023        | 0.020±0.002                       |
| Reference DEXA         | 0.125±0.017        | 0.011±0.003                       |
| ESGWc dilutions        |                    |                                   |
| 100-fold               | 0.162±0.013        | 0.013±0.002                       |
| 200-fold               | 0.181±0.017        | 0.015±0.002                       |
| 400-fold               | 0.198±0.014        | 0.016±0.001                       |
| DNCB                   | 0.242±0.023        | 0.020±0.002                       |
| DEXA                   | 0.125±0.017        | 0.011±0.003                       |
| ESGWc dilutions        |                    |                                   |
| 100-fold               | 0.162±0.013        | 0.013±0.002                       |
| 200-fold               | 0.181±0.017        | 0.015±0.002                       |
| 400-fold               | 0.198±0.014        | 0.016±0.001                       |

Values are expressed as the mean ± standard deviation (n=8). *P<0.05 vs. Intact control; **P<0.05 vs. DNCB control. AD, allergic/atopic-like dermatitis; DNBC, 2,4-dinitrochlorobenzene; DEXA, dexamethasone; ESGWc, east saline ground water concentration solution (50X); LN, lymph node.

Table VII. Changes in splenic cytokine contents after 6 weeks of bathing in ESGWc or topical application of DEXA in mice with DNBC-induced AD.

| Group          | Tumor necrosis factor-α | Interleukin-1β | Interleukin-10 |
|----------------|--------------------------|----------------|----------------|
| Controls       |                          |                |                |
| Intact         | 173.33±31.33             | 53.97±16.10    | 263.06±128.36  |
| DNBC           | 548.44±120.26*           | 207.87±44.12*  | 718.54±141.35* |
| Reference DEXA | 202.07±19.19*            | 97.47±20.38*   | 324.84±83.72*  |
| ESGWc dilutions|                          |                |                |
| 100-fold       | 331.46±39.19*            | 127.57±16.39*  | 435.17±103.85* |
| 200-fold       | 369.29±51.93*            | 136.52±19.78*  | 493.76±96.21*  |
| 400-fold       | 416.41±20.43*            | 153.86±17.10*  | 535.12±101.32* |

Values are expressed as the mean ± standard deviation (n=8). *P<0.05 vs. Intact control; **P<0.05 vs. DNCB control. AD, allergic/atopic-like dermatitis; DNBC, 2,4-dinitrochlorobenzene; DEXA, dexamethasone; ESGWc, east saline ground water concentration solution (50X).

significant decreases in both absolute and relative submandibular LN and spleen weights were detected following topical application of 1% DEXA, and also following bathing in all three ESGWc dilutions, concentration-dependent, compared with DNCB control mice (P<0.05; Table VI).

Effects on splenic cytokine contents. Significant increases in splenic tissue TNF-α, IL-1β and IL-10 contents were detected in DNBC control mice compared with intact control vehicle mice (P<0.05). However, significant decreases in splenic tissue TNF-α, IL-1β and IL-10 contents were detected following topical treatment of 1% DEXA and also concentration-dependent decreases were observed following bathing in ESGWc 100-, 200- and 400-fold dilutions, compared with DNCB control mice (P<0.05; Table VII).

Changes to skin tissue cytokine mRNA expression levels (RT-qPCR analysis). Significant increases in the expression of TNF-α, IL-4, IL-5 and IL-13 mRNA in the dorsal back skin tissue were detected in DNBC control mice compared with intact vehicle control mice according to RT-qPCR analysis (P<0.05; Table VIII). However, significant decreases in expression of TNF-α, IL-4, IL-5 and IL-13 mRNA were observed in skin tissues following topical treatment with 1% DEXA. Concentration-dependent decreases were also observed following bathing in the three dilutions of ESGWc, compared with DNCB control mice (P<0.05; Table VIII).

Effects on the skin tissue antioxidant defense systems. Significant decreases in dorsal back skin tissue GSH content and significant increases in skin lipid peroxidation and
superoxide anion production were observed in DNCB control mice compared with intact vehicle control mice (P<0.05; Table IX). However, compared with DNCB control mice, there were significant increases in GSH content and significantly reduced the increases of mean epithelial thickness due to hyperplasia of red pulp lymphoid tissue, numbers of collagen fiber-occupied dermal regions, caspase-3, PARP, NT and 4-HNE immunoreactive epidermal cells, dermal MMP-9 immunoreactivities, dermal IFN-γ immunolabeled cells and dermal IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cells were also observed in the DNCB control group compared with intact vehicle control group (all P<0.05; Table XI). However, these histopathological hypersensitivity-related AD signs were significantly inhibited by bathing in the ESGWc 100-, 200- and 400-fold dilutions, in a concentration-dependent manner, compared with DNCB control mice (P<0.05; Tables X and XI). Topical application of 1% DEXA also significantly reduced the increases of mean epithelial thickness, numbers of dermal infiltrated mast and inflammatory cells, caspase-3, PARP, NT and 4-HNE immunoreactive epidermal cells, dermal IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cells in DNCB control mice with intact vehicle control mice (all P<0.05; Table XI). However, 1% DEXA did not significantly influence the percentage of collagen fiber-occupied dermal regions, as compared with DNCB control mice (Table X). Abnormal collagen depositions, elevations of caspase-3, PARP, NT and 4-HNE immunoreactive epidermal cells, dermal MMP-9 immunoreactivities, infiltrations of dermal IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cells were significantly reduced by bathing in ESGWc 100-, 200- and 400-fold dilutions, in a concentration-dependent manner, compared with DNCB control mice (P<0.05; Table X). These results were confirmed by histomorphometrical analysis, which demonstrated significant increases in mean epithelial thickness, numbers of dermal infiltrated mast and inflammatory cells, percentages of collagen fiber-occupied dermal regions, caspase-3, PARP, NT and 4-HNE immunoreactive epidermal cells, dermal IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cells in DNCB control mice compared with intact vehicle control mice (all P<0.05; Table XI). However, these histopathological hypersensitivity-related AD signs were significantly inhibited by bathing in the ESGWc 100-, 200- and 400-fold dilutions, in a concentration-dependent manner, compared with DNCB control mice (P<0.05; Tables X and XI). Topical application of 1% DEXA also significantly reduced the increases of mean epithelial thickness, numbers of dermal infiltrated mast and inflammatory cells, caspase-3, PARP, NT and 4-HNE immunoreactive epidermal cells, dermal MMP-9 immunoreactivities, dermal IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cells in DNCB control mice compared with intact vehicle control mice (all P<0.05; Table XI). However, 1% DEXA did not significantly influence the percentage of collagen fiber-occupied dermal regions, as compared with DNCB control mice (Table X).

Abnormal collagen depositions, elevations of caspase-3, PARP, NT and 4-HNE immunoreactive epidermal cells, dermal MMP-9 immunoreactivities, infiltrations of dermal IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cells were also observed in the DNCB control group compared with intact vehicle control group (Figs. 3-5). These results were confirmed by histomorphometrical analysis, which demonstrated significant increases in mean epithelial thickness, numbers of dermal infiltrated mast and inflammatory cells, percentages of collagen fiber-occupied dermal regions, caspase-3, PARP, NT and 4-HNE immunoreactive epidermal cells, dermal IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cells in DNCB control mice compared with intact vehicle control mice (all P<0.05; Table XI). However, these histopathological hypersensitivity-related AD signs were significantly inhibited by bathing in the ESGWc 100-, 200- and 400-fold dilutions, in a concentration-dependent manner, compared with DNCB control mice (P<0.05; Tables X and XI). Topical application of 1% DEXA also significantly reduced the increases of mean epithelial thickness, numbers of dermal infiltrated mast and inflammatory cells, caspase-3, PARP, NT and 4-HNE immunoreactive epidermal cells, dermal MMP-9 immunoreactivities, dermal IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cells induced by NDCB treatment (P<0.05; Tables X and XI); however, 1% DEXA did not significantly influence the percentage of collagen fiber-occupied dermal regions, as compared with DNCB control mice (Table X).

**Histopathological changes in splenic tissues.** Marked hypertrophic changes due to hyperplasia of red pulp lymphoid cells were detected in the splenic tissues of DNCB control mice, with marked increases of the numbers of IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cells (Figs. 6 and 7). These results were confirmed by histomorphometrical analysis, which demonstrated significant increases in total splenic thicknesses, numbers of red pulp lymphoid cells,
Table IX. Changes in skin antioxidant defense systems after 6 weeks of continuous bathing in ESGWc or topical application of DEXA in mice with DNCB-induced AD.

| Groups                        | Glutathione, µM/mg of protein | Lipid peroxidation-Malondialdehyde, nM/mg of protein | Superoxide anion production, NBT reduction/OD at 600 nm |
|-------------------------------|--------------------------------|-----------------------------------------------------|--------------------------------------------------------|
| Controls                      |                                |                                                     |                                                        |
| Intact                        | 1.56±0.32                      | 0.44±0.16                                           | 0.42±0.19                                              |
| DNCB                          | 0.37±0.15                      | 2.87±0.69                                           | 1.80±0.19                                              |
| Reference                     |                                |                                                     |                                                        |
| DEXA                          | 0.34±0.07                      | 3.00±0.95                                           | 1.85±0.18                                              |
| Bathing in ESGWc dilutions    |                                |                                                     |                                                        |
| 100-fold                      | 0.97±0.17                      | 1.26±0.27                                            | 0.91±0.14                                              |
| 200-fold                      | 0.82±0.11                      | 1.49±0.26                                            | 1.12±0.22                                              |
| 400-fold                      | 0.68±0.11                      | 1.83±0.20                                            | 1.26±0.20                                              |

Values are expressed as the mean ± standard deviation (n=8). *P<0.05 vs. Intact control; †P<0.05 vs. DNCB control. AD, allergic/atopic-like dermatitis; DNCB, 2,4-dinitrochlorobenzene; DEXA, dexamethasone; ESGWc, east saline ground water concentration solution (50X); TNF, tumor necrosis factor; OD, optical density; NBT, nitroblue tetrazolium.

Table X. General skin tissue histomorphometry after 6 weeks of bathing in ESGWc or topical application of DEXA in mice with DNCB-induced AD.

| Index                           | Controls | Bathing in ESGWc dilutions |
|---------------------------------|----------|-----------------------------|
|                                 | Intact   | DNCB | DEXA | 100-fold | 200-fold | 400-fold |
| Epithelial Th, µm               | 34.69±8.73 | 117.28±19.66 | 37.07±7.07 | 48.49±11.00 | 54.71±12.06 | 70.53±12.16 |
| Collagen fOP, %/mm² of dermis   | 41.48±3.36 | 77.28±10.51 | 77.58±10.65 | 50.24±10.01 | 55.78±11.16 | 61.86±10.16 |
| Infiltrated cells, cells/mm² of dermis |               |     |     |            |            |          |
| IF                              | 27.13±14.81 | 409.00±76.80 | 74.75±27.06 | 132.75±33.48 | 211.50±44.26 | 283.25±34.05 |
| Mast                            | 134.34±40.05 | 842.75±109.18 | 216.75±44.52 | 381.88±136.05 | 483.75±77.75 | 570.25±111.70 |

Values are expressed as the mean ± standard deviation (n=8). *P<0.05 vs. Intact control; †P<0.05 vs. DNCB control. AD, allergic/atopic-like dermatitis; DNCB, 2,4-dinitrochlorobenzene; DEXA, dexamethasone; ESGWc, east saline ground water concentration solution (50X); Th, thickness; fOP, fiber occupied region percentages; IF, inflammatory.

numbers of IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cells in DNCB control mice compared with intact vehicle control mice (P<0.05; Table XII). However, these hypersensitivity-related splenic hypertrophic signs were significantly inhibited following topical treatment with 1% DEXA, and also by bathing in the three dilutions of ESGWc, concentration-dependently, as compared with DNCB control mice (P<0.05). No significant changes in the number of white pulp cells were demonstrated following treatment with DNCB compared with the intact vehicle control mice, nor by topical application of 1% DEXA or bathing in ESGWc 100-, 200- and 400-fold dilutions, as compared with DNCB control mice (Table XII).

Histopathological changes in submandibular LN tissues. Marked hypertrophic changes due to hyperplasia of cortex lymphoid cells were detected in submandibular LN tissues in DNCB control mice, with marked increases of the numbers of IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cells (Figs. 8 and 9). These observations were confirmed by histomorphometrical analysis, which demonstrated significant increases in total submandibular LN thicknesses, numbers of cortex lymphoid follicles, cortex thicknesses, numbers of IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunolabeled cells in submandibular LN tissues of DNCB control mice compared with intact vehicle control mice (P<0.05; Table XIII). However, these submandibular LN hypersensitivity-related hypertrophic signs were significantly inhibited by topical treatment of
1% DEXA, and also concentration-dependently by bathing in all three dilutions of ESGWc, compared with DNCB control mice (P<0.05; Table XIII).

**Discussion**

In the present study, clinical skin severity and scratching behaviors were significantly reduced, and serum total IgE levels were decreased in mice with DNCB-induced AD following bathing in all ESGWc dilutions, suggesting that bathing in ESGWc inhibited DNCB-induced dermatitis symptoms. Clinical skin severity scores and scratching behaviors were used as an index to select the mice that had developed AD at the end of DNCB sensitization and boosting. Major characteristics of skin lesions of AD are considered to be infiltration with various inflammatory cells, including mast cells, basophils, eosinophils and T cells (29), and symptoms, including itching, erythema, eczema skin lesions, chronic relapse and pruritus (1). DNCB-treated skin exhibits inflammation and dermis sclerosis with these common symptoms (30). Thus, clinical skin severity has been used as a meaningful indicator for predicting the progression of AD with scratching behaviors (3,18). In the current study, clinical skin severity was graded based on five signs, which were pruritus/itching, erythema/hemorrhage, edema, excoriation/erosion, and scaling/dryness. Mast cell-mediated inflammatory responses cause hypersensitivity and allergic reactions. Upon the cross-linking of their surface IgE by antigens, IgE-dependent mast cells may be stimulated to degranulate and release histamine, leukotrienes, proteases, prostaglandins and cytokines (6,18). Mast cell activation results in the release of numerous inflammatory mediators through the cross-linking of IgE receptor complexes at the high-affinity IgE receptor I. Of these mediators, histamine is considered as a marker of mast cell degranulation in immediate allergic reactions and is a violent inducer of itching (6,18). Histamine is a characteristic major mediator in mast cell storage granules and directly triggers type I allergic responses (6,18). Marked increases of infiltrated mast cells have been observed in various types of atopic dermatitis (6,18).

Furthermore, the present study demonstrated that bathing in ESGWc dilutions significantly suppressed DNCB-induced systemic and local hypersensitivities in...
concentration-dependent patterns. TNF-α, IL-1β and IL-10 levels in spleen tissue were markedly reduced, concomitantly TNF-α, IL-4, IL-5 and IL-13 mRNA expression in skin tissue were decreased following bathing in ESGWc dilutions. In addition, bathing in ESGWc dilutions inhibited the IFN-γ, iNOS, IL-1β, IL-2 and TNF-α immunoreactive cells in the local skin, submandibular LN and spleen tissues. It has previously been reported that hydrotherapy, including with ESGW, was able to modulate lymphocyte proliferation and cytokine production (13,18). AD is a form of delayed-type hypersensitivity reaction induced in susceptible individuals by a variety of low molecular weight chemicals (31). The pathogenesis of AD is recognized as a complex process mediated by genetic, environmental and immunological factors (32). IL-4, IL-5 and IL-13 produced by Th2 cells may be responsible for the onset and development of AD (32). Although the etiology and pathology of AD remain unclear, research suggests that typical symptoms of AD include increased levels of Th2-mediated cytokines and a deficiency in Th1-mediated cytokines (33). Th2 cells are primarily involved in the acute phase of AD, while Th1 cells are activated and attribute to pathogenesis in the chronic phase (34). Increased IgE levels are an important indicator of AD and the activation of IL-4 contributes to this elevation. IL-4 triggers IgE production in B cells and IgE released from B cells binds to mast cells. When sufficient antigen has bound to the IgE, the mast cells degranulate and release various biological mediators, including histamine and heparin, which is mediated by IgE in AD (35). AD is dependent on the release of the cytokines IL-4, IL-5, and IL-13 by Th2 cells that are produced from precursors (36). Many patients with AD have experienced an increase in eosinophils and IgE due to elevated IL-4, IL-5 and IL-13 levels (36). TNF-α, a 17-kDa protein that is classified as one of the major products of activated macrophages (37), is a presentative pro-inflammatory cytokine (38). Previous research has demonstrated that TNF-α is markedly increased in DNCB-induced dermatitis (39).

TNF-α-mediated inflammation is stimulated by the release of eicosanoids and cytokines, including IL-1 and TNF-α (38). IL-1 may stimulate neutrophils and macrophages by increasing the production and release of reactive oxygen species (ROS) and nitric oxide, which has been implicated in local tissue damage (40). IL-2 is generally produced by T cells during an immune response and is involved in the growth, proliferation...
Table XI. Immunohistochemical skin tissue histomorphometry after 6 weeks of bathing in ESGWc or topical application of DEXA in mice with DNCB-induced AD.

| Antiserum | Controls | Bathing in ESGWc dilutions |
|-----------|----------|----------------------------|
|           | Intact   | DNBC | DEXA | 100-fold | 200-fold | 400-fold |
| Caspase-3a | 4.75±3.20 | 83.50±11.35 | 35.38±13.36 | 44.25±10.01 | 55.13±12.89 | 65.13±10.27 |
| PARPb     | 6.00±2.27 | 84.63±10.10 | 23.00±4.72 | 35.63±10.95 | 42.25±12.89 | 59.38±13.75 |
| NTc       | 17.13±3.52 | 85.00±10.98 | 18.00±5.07 | 25.13±10.92 | 51.63±11.98 | 61.88±18.65 |
| 4-HNEd    | 5.75±2.49 | 81.83±11.10 | 24.63±4.75 | 31.00±12.49 | 40.75±15.57 | 54.63±10.46 |
| MMP-9e    | 9.24±3.15 | 59.49±11.07 | 42.12±5.25 | 27.15±6.50 | 38.79±5.56 | 45.97±5.54 |
| IFN-γf    | 8.15±2.14 | 153.93±12.2 | 41.29±11.76 | 66.54±16.83 | 84.70±21.85 | 120.74±16.68 |
| iNOSg     | 7.15±1.47 | 240.40±34.21 | 78.05±20.34 | 93.23±15.87 | 165.69±23.82 | 189.61±22.66 |
| IL-1βh    | 5.41±1.54 | 199.48±17.25 | 49.44±12.07 | 85.69±16.49 | 126.81±25.93 | 160.10±20.52 |
| IL-2i     | 4.13±1.15 | 87.08±21.38 | 19.71±5.55 | 37.24±9.30 | 51.58±11.99 | 60.74±11.01 |
| TNF-αj    | 5.64±1.50 | 68.81±14.21 | 18.21±3.25 | 23.74±5.63 | 35.66±10.87 | 42.26±10.10 |

*Number of immunoreactive cells/100 epithelial cells; †% immunoreactivity/mm² of dermis; ‡ x10 immunoreactive cells/mm² of dermis; § P<0.05 vs. Intact control; ¶ P<0.05 vs. DNCB control. Values are expressed as the mean ± standard deviation (n=8). AD, allergic/atopic-like dermatitis; DNCB, 2,4-dinitrochlorobenzene; DEXA, dexamethasone; ESGWc, east saline ground water concentration solution (50X); PARP, cleaved poly(ADP-ribose) polymerase; NT, nitrotyrosine; 4-HNE, 4-hydroxynonenal; MMP, matrix metalloprotease; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; TNF, tumor necrosis factor.

Figure 5. Representative immunohistochemical images of dermal IFN-γ, iNOS, IL-1β, IL-2 and TNF-α in the dorsal back skin tissues taken from unexposed intact mice or mice with DNCB-induced AD following bathing in distilled water or ESGWc, or receiving topical application of DEXA. Immunohistochemical images from (A) intact vehicle control mice bathing in distilled water, (B) DNCB control mice bathing in distilled water, (C) mice with DNCB-induced AD treated with topical application of 1% DEXA and mice with DNCB-induced AD following bathing in ESGWc at (D) 100-, (E) 200- and (F) 400-fold dilution. Scale bar, 40 µm. Stain, avidin-biotin complex immunostain. AD, allergic/atopic-like dermatitis; DNCB, 2,4-dinitrochlorobenzene; DEXA, dexamethasone; ESGWc, east saline groundwater concentration solution (50X); IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; TNF, tumor necrosis factor.
and differentiation of T cells into effector T cells (41). In addition, IL-2 serves an important role in the induction of pruritus in atopic dermatitis (42). IFN-γ is produced by CD8+ T cells, Th1 cells and natural killer (NK) cells in response to IL-2. IFN-γ stimulates NK cell and macrophage activities and also exerts various effects on B and T cells (43). Increases in IFN-γ activities have also been detected in DNCB-induced dermatitis (44). iNOS is involved in the production of nitric oxide from L-arginine. High-output production of iNOS occurs under oxidative conditions. Excess levels of NO may increase the likelihood of interaction with superoxide, leading to peroxynitrite formation and cell toxicity (45). Pro-inflammatory agents, including endotoxin, IL-1β, TNF-α and IFN-γ, may stimulate an increase in iNOS activity (46) and iNOS is also involved in the pathogenesis of atopic dermatitis (18). Therefore, the downregulation of iNOS, IL-2, TNF-α and IFN-γ expression may have protective effects in various allergic diseases. In addition, AD-induced systemic hypersensitivities induce marked proliferation of central and peripheral lymphocytes, particularly T cells (18,31).

As a result, in the present study, depletion of endogenous antioxidant GSH and increases of superoxide anion were significantly inhibited by bathing in ESGWc dilution, which acted as an antioxidant. In addition, epidermal NT and 4-HNE immunoreactive cells were significantly inhibited by bathing in ESGWc dilutions. These findings suggest that bathing in ESGWc dilutions reduces DNCB-induced dermatitis symptoms through potent antioxidative effects. It has been reported that hydrotherapy has potent antioxidant effects on various forms of dermatitis (15,18). Further supporting the antioxidant effects of bathing in ESGWc, previous research has demonstrated that bathing in ESGW inhibited lipid peroxidation, as determined by the MDA concentration of TBARS assay (18). Many toxic substances induce lipid peroxidation damage to the surrounding tissues (47) and AD also causes an imbalance between ROS production and endogenous antioxidant capacity, resulting in depletion of endogenous antioxidants, such as GSH, an epidermal marker that is sensitive to oxidative stress (48). GSH, an important endogenous antioxidant, protects against tissue damage by maintaining ROS at low levels and at certain cellular concentrations (49). The highly polarizable sulfhydryl group of GSH facilitates the scavenging of radicals directly by hydrogen transfer, making it an optimum nucleophile for reactions with electrophilic chemicals (23). Acting as a cofactor for GSH peroxidase and GSH reductase, it may remove hydrogen peroxide and lipid hydroperoxides (50).

The α, β-unsaturated hydroxyalkenal 4-HNE, is generated as a result of lipid peroxidation and is a biomarker for oxidative stress (51). It is also regarded as a potential causal agent of various diseases, including chronic inflammation,
Table XII. Splenic tissue histomorphometry after 6 weeks of bathing in ESGWc or topical application of DEXA in mice with DNCB-induced AD.

| Index                     | Controls                          | Bathing in ESGWc dilutions cells<sup>a</sup> |
|---------------------------|-----------------------------------|-----------------------------------------------|
|                           | Intact                            | DEXA                                          |
|                           | DNCB                              | 100-fold                                      |
|                           |                                   | 200-fold                                      |
|                           |                                   | 400-fold                                      |
| Total Th, mm/central regions | 1.46±0.29                         | 3.47±0.39<sup>d</sup>                         |
|                           |                                   | 1.73±0.20<sup>e</sup>                         |
|                           |                                   | 2.01±0.30<sup>de</sup>                        |
|                           |                                   | 2.24±0.28<sup>de</sup>                        |
|                           |                                   | 2.39±0.38<sup>de</sup>                        |
| White pulp<sup>b</sup>    | 12.13±1.55                        | 13.50±2.56                                    |
|                           |                                   | 12.63±1.41                                    |
|                           |                                   | 12.00±1.77                                    |
|                           |                                   | 13.38±1.69                                    |
|                           |                                   | 13.63±2.26                                    |
| Red pulp<sup>c</sup>      | 2.69±0.56                         | 34.30±10.11<sup>d</sup>                       |
|                           |                                   | 4.98±1.33<sup>de</sup>                        |
|                           |                                   | 9.65±2.99<sup>de</sup>                        |
|                           |                                   | 16.15±2.82<sup>de</sup>                       |
|                           |                                   | 22.29±5.10<sup>de</sup>                       |
| Immunoreactive cells<sup>c</sup> | 15.38±2.00                        | 471.13±88.58<sup>d</sup>                      |
|                           |                                   | 55.38±13.14<sup>de</sup>                      |
|                           |                                   | 127.00±24.17<sup>de</sup>                     |
|                           |                                   | 277.25±60.30<sup>de</sup>                     |
|                           |                                   | 334.38±65.07<sup>de</sup>                     |
|                           | 61.38±14.05                       | 704.50±155.85<sup>d</sup>                     |
|                           |                                   | 144.13±25.39<sup>de</sup>                     |
|                           |                                   | 301.88±40.13<sup>de</sup>                     |
|                           |                                   | 380.00±54.65<sup>de</sup>                     |
|                           |                                   | 513.13±68.77<sup>de</sup>                     |
|                           | 64.00±15.09                       | 829.38±85.72<sup>d</sup>                      |
|                           |                                   | 147.88±27.88<sup>de</sup>                     |
|                           |                                   | 356.25±100.05<sup>de</sup>                    |
|                           |                                   | 556.63±113.03<sup>de</sup>                    |
|                           |                                   | 640.50±115.92<sup>de</sup>                    |
|                           | 143.38±25.16                      | 893.88±170.86<sup>d</sup>                     |
|                           |                                   | 144.38±42.08<sup>de</sup>                     |
|                           |                                   | 368.88±107.94<sup>de</sup>                    |
|                           |                                   | 471.13±140.56<sup>de</sup>                    |
|                           |                                   | 626.13±159.79<sup>de</sup>                    |
|                           | 75.13±14.82                       | 878.00±134.90<sup>d</sup>                     |
|                           |                                   | 150.63±25.40<sup>de</sup>                     |
|                           |                                   | 412.63±60.59<sup>de</sup>                     |
|                           |                                   | 538.00±141.18<sup>de</sup>                    |
|                           |                                   | 651.38±150.39<sup>de</sup>                    |

<sup>a</sup>Number of cells/mm<sup>2</sup> of splenic parenchyma; <sup>b</sup>x10<sup>3</sup> cells/mm<sup>2</sup> of splenic parenchyma; <sup>c</sup>number of immunoreactive cells/mm<sup>2</sup> of splenic parenchyma; <sup>d</sup>P<0.05 vs. Intact control; <sup>e</sup>P<0.05 vs. DNCB control. Values are expressed as the mean ± standard deviation (n=8). AD, allergic/atopic-like dermatitis; DNCB, 2,4-dinitrochlorobenzene; DEXA, dexamethasone; ESGWc, east saline ground water concentration solution (50X); Th, thickness; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; TNF, tumor necrosis factor.

Figure 7. Representative immunohistochemical images of IFN-γ, iNOS, IL-1β, IL-2 and TNF-α in the splenic tissues taken from unexposed intact mice or mice with DNCB-induced AD following bathing in distilled water or ESGWc, or receiving topical application of DEXA. Immunohistochemical images from (A) intact vehicle control mice bathing in distilled water, (B) DNCB control mice bathing in distilled water, (C) mice with DNCB-induced AD treated with topical application of 1% DEXA and mice with DNCB-induced AD after bathing in ESGWc at (D) 100-, (E) 200- and (F) 400-fold dilution. Scale bar, 40 µm. Stain, avidin-biotin complex immunostain. AD, allergic/atopic-like dermatitis; DNCB, 2,4-dinitrochlorobenzene; DEXA, dexamethasone; ESGWc, east saline groundwater concentration solution (50X); IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; TNF, tumor necrosis factor.
neurodegenerative disease, adult respiratory distress syndrome, atherogenesis, diabetes and various types of cancer (51). NT is a product of tyrosine nitration mediated by reactive nitrogen species, including peroxynitrite anion and nitrogen dioxide. It is accepted as a marker of iNOS-dependent, reactive nitrogen species-induced nitrative stress in many pathological conditions (52, 53).

To examine the cytoprotective anti-apoptotic effects of bathing in ESGWc dilutions in the present study, the activities of caspase-3 and PARP were examined in mice with DNCB-induced AD. Bathing in ESGWc dilutions exerted potent keratinocyte protection activity against DNCB-induced epidermal apoptosis by modulating the activities of caspase-3 and PARP. It has been demonstrated that the cleavage of PARP is accompanied by a decrease in enzymatic repair function and consequently leads to the progression of apoptosis (54). Caspase-3 contributes to the cleavage of key nuclear targets in the apoptotic pathway. It contains the inhibitor of caspase-activated deoxyribonuclease, which causes nuclear fragmentation and PARP cleavage, consequently leading to a decrease in DNA repair (55). Thus, caspase-3 is considered to be an important executioner of apoptosis, as it is involved in the proteolytic cleavage of pivotal proteins, such as PARP (56). PARP is a recognized target molecule of caspase-3, which induces the activation of the DNA repair system by caspase-mediated cleavage (57). However, previous studies have reported that overexpression of PARP proteins induced necrosis as intracellular energy levels were decreased through the over-consumption of its substrate, nicotinamide adenine dinucleotide (58-60).

Although the association of PARP with apoptosis and necrosis remains unclear, the suppression of PARP is regarded as a useful strategy for protecting against various forms of skin damage (61) induced by apoptotic changes in DNCB-induced allergic dermatitis (18, 30).

As MMPs are able to degrade various extracellular matrix components and are known to serve important roles in tissue remodeling during developmental morphogenesis, angiogenesis, tissue repair, arthritis, skin aging and tumor invasion (62), the present study examined whether regulation of MMP activity by bathing in ESGWc was involved in DNCB-induced skin sclerosis. The results indicated that bathing in ESGWc (up to 400-fold dilution) exerted strong inhibitory activity against DNCB-induced skin sclerosis by modulating the activities of MMP-9. MMPs, a family of structurally related endopeptidases (63) are categorized into collagenases, gelatinases, stromelysins, membrane-type MMPs and other MMPs, according to their structures and substrate specificities (64).
Table XIII. Submandibular LN tissue histomorphometry after 6 weeks of bathing in ESGWc or topical application of DEXA in mice with DNCB-induced AD.

| Index                               | Controls                              | Bathing in ESGWc dilutions          |
|-------------------------------------|---------------------------------------|-------------------------------------|
|                                     | Intact                                | DEXA 100-fold                       |
|                                     | DNCB                                  | DEXA 200-fold                       |
|                                     |                                       | DEXA 400-fold                       |
|                                     |                                       | 100-fold                            |
|                                     |                                       | 200-fold                            |
|                                     |                                       | 400-fold                            |
| Total Th, mm/central regions         | 0.73±0.13                             | 1.13±0.19d,e                        |
|                                     | 1.89±0.23d                            | 1.21±0.15de                        |
|                                     | 1.02±0.17de                           | 1.39±0.13de                        |
| Folliclesa                          | 12.50±1.93                            | 17.88±2.75de                        |
|                                     | 35.00±5.40d                           | 19.63±2.97de                        |
|                                     | 16.00±2.45de                          | 26.25±6.30de                        |
| Cortex Tb                          | 364.96±112.92                         | 566.65±143.70de                     |
|                                     | 987.27±146.47d                        | 759.54±109.37de                     |
|                                     | 431.98±86.57d                         | 804.96±92.38de                      |
| Immunoreactive cellsc              |                                       |                                     |
| TNF-α                               | 7.23±1.26                             | 34.21±9.08de                        |
|                                     | 139.63±34.18d                         | 46.71±12.43de                       |
|                                     | 23.23±8.57d,e                         | 75.45±21.96de                       |
| IFN-γ                               | 9.31±2.37                             | 74.94±21.86de                       |
|                                     | 217.28±23.00d                        | 119.58±26.28de                      |
|                                     | 21.20±7.38d,e                         | 177.78±22.73de                      |
| iNOS                                | 9.39±3.04                             | 42.69±15.02de                       |
|                                     | 167.09±31.30d                        | 55.13±12.98de                       |
|                                     | 21.43±8.37d,e                         | 63.11±12.43de                       |
| IL-1β                               | 14.11±3.65                            | 54.50±15.18de                       |
|                                     | 135.53±21.48d                        | 72.50±10.25de                       |
|                                     | 49.26±13.39d,e                       | 99.44±15.76de                       |
| IL-2                                | 3.24±1.35                             | 26.16±11.27de                       |
|                                     | 89.48±12.43d                         | 39.79±11.69de                       |
|                                     | 19.19±7.30d,e                         | 48.91±18.70de                       |

| Notes: | Numbers/mm² of cortex; µm/LN; x10 cells/mm² of LN parenchyma; P<0.05 vs. Intact control; *P<0.05 vs. DNCB control. Values are expressed as the mean ± standard deviation (n=8). LN, lymph node; AD, allergic/atopic-like dermatitis; DNCB, 2,4-dinitrochlorobenzene; DEXA, dexamethasone; ESGWc, east saline groundwater concentration solution (50X); Th, thickness; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; TNF, tumor necrosis factor.

Figure 9. Representative immunohistochemical images of IFN-γ, iNOS, IL-1β, IL-2 and TNF-α in the submandibular LN tissues taken from unexposed intact mice or mice with DNCB-induced AD following bathing in distilled water or ESGWc, or receiving topical application of DEXA. Immunohistochemical images from (A) intact vehicle control mice bathing in distilled water, (B) DNCB control mice bathing in distilled water, (C) mice with DNCB-induced AD treated with topical application of 1% DEXA and mice with DNCB-induced AD after bathing in ESGWc at (D) 100-, (E) 200- and (F) 400-fold dilution. Scale bar=40 µm. Stain, avidin-biotin complex immunostain. AD, allergic/atopic-like dermatitis; DNCB, 2,4-dinitrochlorobenzene; DEXA, dexamethasone; ESGWc, east saline groundwater concentration solution (50X); IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; TNF, tumor necrosis factor.
Levels of MMPs are usually low in unstimulated skin tissues and levels are upregulated following exposure to various extracellular stimuli, including ultraviolet light, growth factors, cytokines and tumor promoters (64,65). Previous studies have indicated that there was a significant increase in a number of MMPs, particularly MMP-8 and MMP-9, in AD patients (66,67). Such research suggests that reducing MMP activity may be a protective approach to attenuate AD-related skin sclerosis (18,68).

The results obtained in the present study suggest that bathing in all three concentrations (100-, 200- and 400-fold dilutions) of ESGWC has favorable protective effects against DNBC-induced AD. It was demonstrated that ESGWC has favorable systemic and local immunomodulatory effects, active cytoprotective anti-apoptotic effects, inhibitory effects of MMP activity, anti-inflammatory and antioxidative effects, in a concentration-dependent manner. In conclusion, bathing in ESGWC, may provide an alternative therapy for patients with AD in the future, at least under the conditions of this experiment. Topical application of 1% DEXA also significantly inhibited the DNBC-induced AD; however, it did not influence dermal collagen depositions and skin tissue antioxidative defense systems in the present experiment.

Acknowledgements

The present study was supported by the Republic of Korea Institute of Ocean Science and Technology (grant no. PE99365) and the National Research Foundation of Korea grant funded by the Korea government (grant no. 2012R1A5A2A42671316).

References

1. Leung DY: Atopic dermatitis: New insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 105: 860-870, 2000.
2. Thestrup-Pedersen K: Clinical aspects of atopic dermatitis. Clin Exp Dermatol 25: 535-543, 2000.
3. Park G and Oh MS: Inhibitory effects of Juglans mandshurica leaf on allergic dermatitis-like skin lesions-induced by 2,4-dinitrochlorobenzene in mice. Exp Toxicol Pathol 66: 97-101, 2014.
4. Saeki H, Furue M, Furukawa F, Hide M, Ohtsuki M, Katayama I, Sasaki R, Suto H and Takehara K; Committee for guidelines for the management of atopic dermatitis of Japanese dermatological association: Guidelines for management of atopic dermatitis. J Dermatol 36: 563-577, 2009.
5. Pugliarello S, Cozzi A, Gisondi P and Girolomoni G: Phenotypes of atopic dermatitis. J Dtsch Dermatol Ges 9: 12-20, 2011 (In English; In German).
6. Kim SR, Choi HS, Seo HS, Choi YK, Shin YC and Ko SG: Topical application of herbal mixture extract inhibits ovalbumin-or 2,4-dinitrochlorobenzene-induced atopic dermatitis. Evid Based Complement Alternat Med 2012: 645-497, 2012.
7. Koga C, Kabashima K, Shiraishi N, Kobayashi M and Tokura Y: Possible pathogenic role of Th17 cells for atopic dermatitis. J Dtsch Dermatol Ges 12: 632-646, 2015.
8. Okayama Y: Oxidative stress in allergic and inflammatory skin diseases. Curr Drug Targets Inflamm Allergy 4: 402-408, 2005.
9. Tsakiris A: Anti-inflammatory drugs. Drugs of today 22: 101-133, 1986.
10. Merial-Kieny C, Mengual X, Guerrero D and Sibaud V: Clinical efficacy of Avène hydrotherapy measured in a large cohort of more than 10,000 atopic or psoriatic patients. J Eur Acad Dermatol Venereol 25 (Suppl 1): S30-S34, 2011.
11. Brockow T, Schieri R, Franke A, Resch KL and Peter RU: A pragmatic randomized controlled trial on the effectiveness of concentrated saline water spa baths followed by ultraviolet B (UVB) compared to UVB only in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 21: 1027-1037, 2007.
31. Lee JK, Park JH, Park SH, Kim HS and Oh HY: A nonradioisotopic endpoint for measurement of lymph node cell proliferation in a murine allergic contact dermatitis model, using bromodeoxyuridine immunohistochemistry. J Pharmacol Toxicol Methods 48: 53-61, 2002.

32. Choi JH, Kim HG, Jin SW, Han EH, Khanal T, Do MT, Hwang YP, Choi JM, Chun SS, Chung YC, et al.: Topical application of Pleurotus eryngii extracts inhibits 2,4-dinitrochlorobenzene-induced atopic dermatitis in NC/Nga mice by the regulation of Th1/Th2 balance. Food Chem Toxicol 53: 38-45, 2013.

33. Sawada E, Yoshida N, Sugiaura A and Imokawa G: Th1 cytokines accentuate but Th2 cytokines attenuate ceramide production in the stratum corneum of human epidermal equivalents: An implication for the disrupted barrier mechanism in atopic dermatitis. J Dermatol Sci 68: 25-35, 2012.

34. Vestergaard C, Yoneyama H, Murai M, Nakamura K, Tamaki K, Terashima Y, Imai T, Yoshie O, Irimura T, Mizutani H and Matsushima K: Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J Clin Invest 104: 1097-1105, 1999.

35. Poulsen LK and Hummelshoj L: Triggers of IgE class switching and allergy development. Ann Med 39: 440-459, 2007.

36. Yamanaka K and Mizutani H: The role of cytokines/chemokines in the pathogenesis of atopic dermatitis. Curr Probl Dermatol 41: 19-92, 2011.

37. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, Ulevitch R and Cerami A: Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316: 552-554, 1985.

38. Whittle BJ, Varga C, Berko A, Horvath K, Posa A, Riley JP, Lundeen KA, Fournier AM and Dunford PJ: Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. Br J Pharmacol 153: 983-991, 2008.

39. Schottelius AJ, Zügel U, Döcke WD, Zöllner TM, Röse L, Mengel A, Buchmann B, Becker A, Grütt G, Naundorf S, et al.: The role of mitogen-activated protein kinase 2 in the p38 κβ transcriptional activity by preventing p65 de-acetylation. Br J Dermatol 126: 1833-1841, 1992.

40. Nagase H and Woessner JF Jr: Matrix metalloproteinases in a murine allergic contact dermatitis model, using bromodeoxyuridine immunohistochemistry. J Pharmacol Toxicol Methods 48: 53-61, 2002.

41. Sivaramani N, Rao SV and Rajeev G: Role of reactive oxygen species and antioxidants in atopic dermatitis. J Clin Diagn Res 7: 2683-2685, 2013.

42. Odayaboglu F, Cukir A, Suleyman H, Aslan A, Bayir Y, Halici M and Kazaz C: Gastroprotective and antioxidant effects of ursolic acid on indomethacin-induced gastric ulcer in rats. J Ethnopharmacol 103: 59-65, 2006.

43. Pinell SR: Cutaneous photodamage, oxidative stress, and topical antioxidant protection. J Am Acad Dermatol 48: 1-19, 2003.

44. Dubinina EE and Dadali VA: Role of 4-hydroxy-trans-2-nonenal in cell functions. Biochemistry (Mosc) 75: 1069-1087, 2010.

45. Mohiuddin I, Chai H, Lin PH, Lamsden AB, Yao Q and Chen C: Nitrotyrosine and chlorotyrosine: Clinical significance and biological functions in the vascular system. J Surg Res 133: 143-149, 2006.

46. Pacher P, Beckmann JS and Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007.

47. Smulson ME, Pang D, Jung M, Dimitchev A, Chasovskikh S, Spoone A, Simbulan-Rosenthal C, Rosenthal D, Yakovlev A and Dritschilo A: Irreversible binding of poly(ADP)ribose polymerase cleavage product to DNA ends revealed by atomic force microscopy: Possible role in apoptosis. Cancer Res 58: 3495-3498, 1998.

48. Smyth PG and Berman SA: Markers of apoptosis: Methods for elucidating the mechanism of apoptotic cell death from the nervous system. Biotechniques 32: 648-650, 652, 654 passim, 2002.

49. Fernandes-Alnemri T, Litwack G and Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1β-converting enzyme. J Biol Chem 269: 30761-30764, 1994.

50. Tewari M, Quan LT, O’Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM: Yama/CPP32b, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809, 1995.

51. Li H, Li Q, Li W, Xie L, Zhou M and Xie J: The role of PARP-1 in host pathogen interaction and cellular stress responses. Crit Rev Eukaryot Gene Expr 25: 175-190, 2015.

52. Virag L: Structure and function of poly(ADP-ribose) polymerase-1: Role in oxidative stress-related pathologies. Curr Pharm Pharmacol 3: 209-214, 2005.

53. Kauppinen TM, Gan L and Swanson RA: Poly(ADP-ribose) polymerase-1 induced NAD(+) depletion promotes nuclear factor-kappaB transcriptional activity by preventing p65 de-acetylation. Biochim Biophys Acta 1833: 1885-1901, 2013.

54. Cole KK and Perez-Polo JR: Poly(ADP-ribose) polymerase inhibition prevents both apoptotic-like delayed neuronal death and necrosis after H(2)O(2)/injury. J Neurochem 80: 19-29, 2002.

55. Kähäri VM and Saarialho-Kere U: Matrix metalloproteinases in skin. Exp Dermatol 6: 199-213, 1997.

56. Jin JX, Kim EJ, Oh IK, Kim YK, Park CH and Chung JH: Prevention of UV-induced skin damages by 11,14,17-eicosatrienoic acid in hairless mice in vivo. J Korean Med Sci 25: 930-937, 2010.

57. Pacher P, Beckmann JS and Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007.

58. Smulson ME, Pang D, Jung M, Dimitchev A, Chasovskikh S, Spoone A, Simbulan-Rosenthal C, Rosenthal D, Yakovlev A and Dritschilo A: Irreversible binding of poly(ADP)ribose polymerase cleavage product to DNA ends revealed by atomic force microscopy: Possible role in apoptosis. Cancer Res 58: 3495-3498, 1998.

59. Smyth PG and Berman SA: Markers of apoptosis: Methods for elucidating the mechanism of apoptotic cell death from the nervous system. Biotechniques 32: 648-650, 652, 654 passim, 2002.

60. Fernandes-Alnemri T, Litwack G and Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1β-converting enzyme. J Biol Chem 269: 30761-30764, 1994.